TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28379954

Group type: EXPERIMENTAL
Intervention: Miltefosine
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Meglumine antimoniate (MA)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Age ≤8 years
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Disease duration ≤1 month
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Regional lymphadenopathy
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Adherence <90%
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Higher Z-score of height/age (in children)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Meglumine antimoniate (MA) (in children)
Number of subjects: 230
Study: 28380308

Group type: EXPERIMENTAL
Intervention: PiMZ genotype
Number of subjects: 8271

Group type: COMPARATOR
Intervention: Z-allele noncarriers
Number of subjects: 8271
Study: 28381130

Group type: EXPERIMENTAL
Intervention: Autologous MSC transplantation
Number of subjects: 24
Study: 28381220

Group type: EXPERIMENTAL
Intervention: mpMRI-targeted biopsies
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: CEUS-targeted biopsies
Number of subjects: 299

Group type: COMPARATOR
Intervention: Systematic TRUS-guided biopsies
Number of subjects: 299
Study: 28381249

Group type: EXPERIMENTAL
Intervention: Point-of-care alert for cardioprotective medications
Number of subjects: 10
Study: 28381395

Group type: EXPERIMENTAL
Intervention: Mobile tailored information app for chronic disease self-management
Number of subjects: 0
Study: 28381434

Group type: EXPERIMENTAL
Intervention: Microscopic observation drug susceptibility assay
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 28381473

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 28381476

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sedentary time
Number of subjects: 0
Study: 28381477

Group type: EXPERIMENTAL
Intervention: Enteropathogen exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (healthy children)
Number of subjects: 0
Study: 28382208

Group type: EXPERIMENTAL
Intervention: Etravirine 200 mg bid with ≥1 other active antiretroviral (excluding darunavir/ritonavir)
Number of subjects: 211
Study: 28382379

Group type: EXPERIMENTAL
Intervention: Erlotinib with concurrent and sequential radiotherapy
Number of subjects: 22
Study: 28382529

Group type: EXPERIMENTAL
Intervention: Self-detected metabolic system (MS)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Experts' visual (V) readings
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Software using a log-log transformation (LLT)
Number of subjects: 140
Study: 28382566

Group type: EXPERIMENTAL
Intervention: TIMP-2*IGFBP-7 concentration measured at 12 hours after CPB initiation
Number of subjects: 94
Study: 28383392

Group type: EXPERIMENTAL
Intervention: Valganciclovir, 17 mg/kg once daily
Number of subjects: 13
Study: 28383677

Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg/day until disease progression or unacceptable toxicity
Number of subjects: 43
Study: 28384199

Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists (VKA)
Number of subjects: 7154

Group type: EXPERIMENTAL
Intervention: Direct anticoagulants (DOAC)
Number of subjects: 7154

Group type: COMPARATOR
Intervention: General practitioners' perception
Number of subjects: 7154
Study: 28384285

Group type: EXPERIMENTAL
Intervention: BNP
Number of subjects: 1617

Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 1617

Group type: EXPERIMENTAL
Intervention: Troponin T
Number of subjects: 1617

Group type: EXPERIMENTAL
Intervention: Troponin I
Number of subjects: 1617

Group type: EXPERIMENTAL
Intervention: Mortality
Number of subjects: 1617

Group type: EXPERIMENTAL
Intervention: Overall-survival estimates
Number of subjects: 1617

Group type: EXPERIMENTAL
Intervention: Cox proportional hazards model
Number of subjects: 1617
Study: 28385065

Group type: EXPERIMENTAL
Intervention: Raltegravir (RAL) 400 mg BID
Number of subjects: 451
Study: 28385306

Group type: EXPERIMENTAL
Intervention: Gallium-68-labeled DOTATATE
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluorine-18-labeled fluorodeoxyglucose positron emission tomography
Number of subjects: 0
Study: 28385308

Group type: EXPERIMENTAL
Intervention: Transcatheter device implantation
Number of subjects: 15
Study: 28386037

Group type: EXPERIMENTAL
Intervention: Artificial intelligence platform for daily monitoring
Number of subjects: 28

Group type: COMPARATOR
Intervention: No daily monitoring (control)
Number of subjects: 28
Study: 28387632

Group type: EXPERIMENTAL
Intervention: Second-window indocyanine green (ICG) 5 mg/kg injected the day prior to surgery
Number of subjects: 18
Study: 28387950

Group type: EXPERIMENTAL
Intervention: Treprostinil cutaneous iontophoresis
Number of subjects: 0
Study: 28388260

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1132

Group type: EXPERIMENTAL
Intervention: FVC decline >= 10% to < 15%
Number of subjects: 1132

Group type: EXPERIMENTAL
Intervention: FVC decline >= 15%
Number of subjects: 1132

Group type: EXPERIMENTAL
Intervention: FVC decline > 5% to < 10%
Number of subjects: 1132
Study: 28388657

Group type: EXPERIMENTAL
Intervention: CRT-D implantation
Number of subjects: 305
Study: 28388956

Group type: EXPERIMENTAL
Intervention: 20 mg of prednisolone for 3 days (days 3-5) along with 1 g of paracetamol per day for 5 days for pain relief.
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Pred-test (20 mg of prednisolone for 3 days)
Number of subjects: 95
Study: 28388966

Group type: EXPERIMENTAL
Intervention: Vaccination with peptide-pulsed dendritic cells and poly-ICLC
Number of subjects: 12
Study: 28389304

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid (ICS) with add-on therapy
Number of subjects: 171

Group type: COMPARATOR
Intervention: No specific intervention mentioned
Number of subjects: 171
Study: 28389391

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28389393

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28389462

Group type: EXPERIMENTAL
Intervention: High-dose araC (HD-araC) used in the second induction cycle
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: MRD-negative patients (n = 125)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: MRD-positive patients (n = 21)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Refractory/relapsed leukemia patients (n = 17)
Number of subjects: 204
Study: 28389617

Group type: EXPERIMENTAL
Intervention: Dedicated Spanish language enrollment line
Number of subjects: 1700

Group type: COMPARATOR
Intervention: Non-Spanish language enrollment
Number of subjects: 1700
Study: 28390410

Group type: EXPERIMENTAL
Intervention: Pentasa® 4000 mg/day in 2 divided doses
Number of subjects: 5695

Group type: EXPERIMENTAL
Intervention: Asacol® 3600 mg/day in 3 divided doses
Number of subjects: 5695

Group type: EXPERIMENTAL
Intervention: Duration of remission maintenance until enrollment 12 to <24 months
Number of subjects: 5695

Group type: EXPERIMENTAL
Intervention: Duration of remission maintenance until enrollment ≥24 months
Number of subjects: 5695
Study: 28390437

Group type: EXPERIMENTAL
Intervention: Medication overuse headache (MOH) patients
Number of subjects: 0
Study: 28390587

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 39
Study: 28390663

Group type: EXPERIMENTAL
Intervention: Sagittal abdominal diameter (SAD) >25 cm
Number of subjects: 635

Group type: COMPARATOR
Intervention: Waist circumference (WC)
Number of subjects: 635
Study: 28391003

Group type: EXPERIMENTAL
Intervention: Surgery alone
Number of subjects: 60
Study: 28391235

Group type: EXPERIMENTAL
Intervention: Postoperative serum albumin drop (ΔAlb) ≥10 g/L on postoperative day 1 (POD 1)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Postoperative serum albumin drop (ΔAlb)
Number of subjects: 138
Study: 28391409

Group type: EXPERIMENTAL
Intervention: Comprehensive medication reviews conducted by clinical pharmacists
Number of subjects: 230

Group type: COMPARATOR
Intervention: Control group (no pharmacist participation)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Comprehensive medication reviews conducted by clinical pharmacists (after adjustment for heart failure)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Post-hoc analysis of comprehensive medication reviews
Number of subjects: 230
Study: 28391893

Group type: EXPERIMENTAL
Intervention: Omega-3 Index (total n-3 PUFAs)
Number of subjects: 6501

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA)
Number of subjects: 6501

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA)
Number of subjects: 6501

Group type: EXPERIMENTAL
Intervention: PUFA factor score (calculated variable including 6 PUFAs)
Number of subjects: 6501
Study: 28391894

Group type: EXPERIMENTAL
Intervention: National genetic cascade screening program for FH (NPFH)
Number of subjects: 9000

Group type: COMPARATOR
Intervention: Usual clinical care
Number of subjects: 9000
Study: 28392491

Group type: EXPERIMENTAL
Intervention: Intrinsic functional connectivity of the central nucleus of the amygdala (CeA)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Intrinsic functional connectivity of the bed nucleus of the stria terminalis (BNST)
Number of subjects: 27
Study: 28393103

Group type: EXPERIMENTAL
Intervention: PICOPREP tailored dosing
Number of subjects: 0

Group type: COMPARATOR
Intervention: PICOPREP day-before dosing
Number of subjects: 0
Study: 28393655

Group type: EXPERIMENTAL
Intervention: Chewing side preference (CSP)
Number of subjects: 75
Study: 28393673

Group type: EXPERIMENTAL
Intervention: Pantheris catheter alone
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Pantheris + adjunctive therapy
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Pantheris alone
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Composite major adverse events (MAEs)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Histological analysis of atherectomy specimens
Number of subjects: 158
Study: 28394435

Group type: EXPERIMENTAL
Intervention: Oral anticoagulant (OAC) therapy
Number of subjects: 1170

Group type: COMPARATOR
Intervention: Non-anticoagulant treatment
Number of subjects: 1170
Study: 28395663

Group type: EXPERIMENTAL
Intervention: Liver transplantation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Post-cardiac surgery patients (controls)
Number of subjects: 12
Study: 28395671

Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 41
Study: 28395880

Group type: EXPERIMENTAL
Intervention: Adoptive transfer of autologous tumour-infiltrating lymphocytes (TILs)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Lymphodepleting chemotherapy (intravenous cyclophosphamide [60 mg/kg] daily for 2 days followed by fludarabine [25 mg/m2])
Number of subjects: 21

Group type: COMPARATOR
Intervention: Lymphodepleting chemotherapy
Number of subjects: 21
Study: 28395998

Group type: EXPERIMENTAL
Intervention: Collagenase Clostridium histolyticum (CCH) intralesional injection (0.58 mg/injection, up to eight injections)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: CCH treatment of male partners
Number of subjects: 189
Study: 28396040

Group type: EXPERIMENTAL
Intervention: Left Ventricular Assist Device (LVAD)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Optimal Medical Management (OMM)
Number of subjects: 200
Study: 28396050

Group type: EXPERIMENTAL
Intervention: Patient-specific instrumentation (PSTs)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: CUSUM test
Number of subjects: 50
Study: 28397471

Group type: EXPERIMENTAL
Intervention: Hyperhomocysteinemia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High Hcy and MTHFR1298AC + CC genotypes
Number of subjects: 0
Study: 28397698

Group type: EXPERIMENTAL
Intervention: Ledipasvir-sofosbuvir once daily for 6 weeks
Number of subjects: 26
Study: 28398006

Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention
Number of subjects: 144
Study: 28398341

Group type: EXPERIMENTAL
Intervention: CACNA1C allele A carriers
Number of subjects: 117

Group type: COMPARATOR
Intervention: Non-carriers of CACNA1C allele A
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: All subjects (regardless of CACNA1C rs1006737 A status)
Number of subjects: 117
Study: 28399802

Group type: EXPERIMENTAL
Intervention: Isoniazid (INH) with rifapentine once weekly for 12 weeks (INH/RPT-3)
Number of subjects: 44149

Group type: EXPERIMENTAL
Intervention: 6 months of daily INH (INH-6)
Number of subjects: 44149

Group type: EXPERIMENTAL
Intervention: 9 months of daily INH (INH-9)
Number of subjects: 44149

Group type: EXPERIMENTAL
Intervention: 3-4 months daily INH plus rifampicin (INH/RFMP 3-4)
Number of subjects: 44149

Group type: EXPERIMENTAL
Intervention: 4 months daily rifampicin alone (RFMP-4)
Number of subjects: 44149

Group type: EXPERIMENTAL
Intervention: 3-4 months regimens
Number of subjects: 44149

Group type: COMPARATOR
Intervention: Active regimens
Number of subjects: 44149

Group type: EXPERIMENTAL
Intervention: Shorter rifamycin-based regimens
Number of subjects: 44149

Group type: EXPERIMENTAL
Intervention: Longer regimens
Number of subjects: 44149
Study: 28399804

Group type: EXPERIMENTAL
Intervention: Abacavir-containing treatment
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: HLA-B*57:01 allele testing
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: HLA-B*57:01 allele prevalence
Number of subjects: 385
Study: 28399815

Group type: EXPERIMENTAL
Intervention: cART initiation
Number of subjects: 48
Study: 28399830

Group type: EXPERIMENTAL
Intervention: Electromagnetic navigation bronchoscopy (ENB) for lung lesion biopsy
Number of subjects: 1000
Study: 28399845

Group type: EXPERIMENTAL
Intervention: Community-based network promoting smoking cessation services
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Community model of promoting gender-specific smoking cessation services
Number of subjects: 623
Study: 28399850

Group type: EXPERIMENTAL
Intervention: General Oral Health Assessment Index (GOHAI)
Number of subjects: 90
Study: 28399887

Group type: EXPERIMENTAL
Intervention: Food purchases (HEI-2010 scores)
Number of subjects: 196

Group type: COMPARATOR
Intervention: 24-h diet recalls (HEI-2010 scores)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Food purchases (individual nutrient densities)
Number of subjects: 196
Study: 28399921

Group type: EXPERIMENTAL
Intervention: Endocrine therapy + dasatinib (p-Src kinase inhibitor)
Number of subjects: 509

Group type: COMPARATOR
Intervention: Endocrine therapy
Number of subjects: 509
Study: 28399931

Group type: EXPERIMENTAL
Intervention: Biologic CTP (IL1 inhibitor [IL1i] ± GC, IL6 inhibitor [IL6i] ± GC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-biologic CTP (glucocorticoid [GC] alone, methotrexate [MTX] ± GC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Overall (all CTPs)
Number of subjects: 30
Study: 28400193

Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stem cells applied in a bioabsorbable matrix
Number of subjects: 12
Study: 28400218

Group type: EXPERIMENTAL
Intervention: Heparin-coated stent grafts
Number of subjects: 103

Group type: COMPARATOR
Intervention: Above-knee bypass surgery (historical control)
Number of subjects: 103
Study: 28400935

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 28401454

Group type: EXPERIMENTAL
Intervention: Flash Glucose Monitoring System (FreeStyle Libre™)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Self-Monitoring Blood Glucose (SMBG) (FreeStyle Lite™)
Number of subjects: 224
Study: 28402487

Group type: EXPERIMENTAL
Intervention: serum klotho (seKL) ≥280 ng/L
Number of subjects: 238

Group type: COMPARATOR
Intervention: serum klotho (seKL) <280 ng/L
Number of subjects: 238
Study: 28403013

Group type: EXPERIMENTAL
Intervention: V2 receptor blockade
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Changes in daily water intake
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study: 28403055

Group type: EXPERIMENTAL
Intervention: PHiD-CV vaccine administered to children <6 months (3 primary doses + booster)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: PHiD-CV vaccine administered to children 7-11 months (2 primary doses + booster)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: PHiD-CV vaccine administered to children 12-23 months (2 catch-up doses)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: PHiD-CV vaccine
Number of subjects: 300
Study: 28403119

Group type: EXPERIMENTAL
Intervention: Combined measurement of soluble ST2 (≥ 500 ng/mL) and amino-terminal pro-B-type natriuretic peptide (≥ 4,500 ng/L) at 12 hours
Number of subjects: 145

Group type: COMPARATOR
Intervention: CardShock risk score
Number of subjects: 145
Study: 28403407

Group type: EXPERIMENTAL
Intervention: THRIVE (Transnasal Humidified Rapid-Insufflation Ventilatory Exchange), 100% oxygen, 40-70 litres min - 1
Number of subjects: 31

Group type: COMPARATOR
Intervention: Hyperventilation during pre-oxygenation
Number of subjects: 31
Study: 28403822

Group type: EXPERIMENTAL
Intervention: Acupuncture and chiropractic (A/C) services
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Education about realistic expectations for chronic pain management and therapy options
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Access to A/C care
Number of subjects: 90
Study: 28403842

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cell transplantation
Number of subjects: 12
Study: 28403962

Group type: EXPERIMENTAL
Intervention: Robotic assistance in surgery for deep infiltrating endometriosis
Number of subjects: 35
Study: 28404357

Group type: EXPERIMENTAL
Intervention: qHPV vaccine
Number of subjects: 34
Study: 28404577

Group type: EXPERIMENTAL
Intervention: Reduced schedule of therapeutic food distribution
Number of subjects: 0
Study: 28404672

Group type: EXPERIMENTAL
Intervention: Mycobacterium tuberculosis mutations conferring resistance to second-line antituberculous drugs
Number of subjects: 0
Study: 28404690

Group type: EXPERIMENTAL
Intervention: Valbenazine (NBI-98854)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Valbenazine metabolites
Number of subjects: 0
Study: 28405211

Group type: EXPERIMENTAL
Intervention: Breastfeeding initiation
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Breastfeeding knowledge scores
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Breastfeeding belief scores
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Breastfeeding duration
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Breastfeeding intent and beliefs
Number of subjects: 82
Study: 28405328

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) using polyhematoporphyrin
Number of subjects: 88
Study: 28405331

Group type: EXPERIMENTAL
Intervention: Gradual stiffness colonoscopes
Number of subjects: 475

Group type: COMPARATOR
Intervention: MEI-guided variable stiffness colonoscopes
Number of subjects: 475
Study: 28405343

Group type: EXPERIMENTAL
Intervention: Community-based self-help intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: KAs with DM
Number of subjects: 0

Group type: COMPARATOR
Intervention: All Americans with DM
Number of subjects: 0

Group type: COMPARATOR
Intervention: All Americans without DM
Number of subjects: 0

Group type: COMPARATOR
Intervention: All Americans with/without DM
Number of subjects: 0
Study: 28405344

Group type: EXPERIMENTAL
Intervention: Mediterranean-style diet and increased walking (Phase I: months 1-6)
Number of subjects: 124
Study: 28405346

Group type: EXPERIMENTAL
Intervention: Saxagliptin
Number of subjects: 66

Group type: COMPARATOR
Intervention: Basal-bolus insulin
Number of subjects: 66
Study: 28405470

Group type: EXPERIMENTAL
Intervention: VEGF concentration at week 0 in patients with GCA
Number of subjects: 298

Group type: COMPARATOR
Intervention: VEGF concentration at week 0 in controls
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Sensitivity and specificity of VEGF concentration at the optimal cut-off of 713 pg/mL applied to the whole cohort
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Sensitivity and specificity of VEGF concentration comparing biopsy-proven GCA to controls
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Immunohistochemistry staining of biopsy from biopsy-positive GCA
Number of subjects: 298
Study: 28405472

Group type: EXPERIMENTAL
Intervention: jSpA treatment (exact intervention not specified)
Number of subjects: 118
Study: 28405473

Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg QD
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg QD
Number of subjects: 684

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 684
Study: 28406269

Group type: EXPERIMENTAL
Intervention: Community-led health campaign (CLHC)
Number of subjects: 2753
Study: 28406555

Group type: EXPERIMENTAL
Intervention: Clinical and biological predictors of disease course and outcome in GBS
Number of subjects: 1400

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid and serial blood samples for serum and DNA
Number of subjects: 1400
Study: 28406674

Group type: EXPERIMENTAL
Intervention: Caffeine (exact dosage and duration not specified)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28406934

Group type: EXPERIMENTAL
Intervention: Dopamine-Transporter (DaT) SPECT imaging in PD patients
Number of subjects: 80

Group type: COMPARATOR
Intervention: Dopamine-Transporter (DaT) SPECT imaging in NMC
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Dopamine-Transporter (DaT) SPECT imaging in NMC participants who later phenoconverted into PD
Number of subjects: 80
Study: 28406940

Group type: EXPERIMENTAL
Intervention: Antithrombin III (ATIII) activity on POD1
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: ATIII activity <61.5%
Number of subjects: 228
Study: 28407138

Group type: EXPERIMENTAL
Intervention: ACM group
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: After treatment of acromegaly
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study: 28407139

Group type: EXPERIMENTAL
Intervention: Remote Monitoring (RM)
Number of subjects: 858

Group type: COMPARATOR
Intervention: Standard Management (SM)
Number of subjects: 858

Group type: EXPERIMENTAL
Intervention: Remote Monitoring (RM) after propensity score matching
Number of subjects: 858

Group type: COMPARATOR
Intervention: Standard Management (SM) after propensity score matching
Number of subjects: 858
Study: 28407216

Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy
Number of subjects: 6273
Study: 28407492

Group type: EXPERIMENTAL
Intervention: Discontinuation of anticoagulation in patients without RVT and negative D-dimer
Number of subjects: 620

Group type: COMPARATOR
Intervention: Anticoagulation
Number of subjects: 620